Clinical Trial

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Study acronym: SCST-01
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2023 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2015-04-24; most recent amendment 2023-04-22.
Status change: Enrolling by Invitation → Recruiting 2018-08-15
Status change: Active, Not Recruiting → Enrolling by Invitation 2016-02-14
Trial Details
NCT Number NCT02429700
Lead Sponsor Beihua Kong
Collaborators: Huazhong University of Science and Technology, Zhejiang University, Sun Yat-sen University
Conditions Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer
Enrollment 132 participants
Start Date 2015-04
Primary Completion 2025-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2023-04-25